Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR)
Ayurveda Zaynabila Heriqbaldi
Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
First-Line Anti-Tuberculosis Drug Resistance Pattern Ayurveda Zaynabila Heriqbaldi; Rebekah Juniati Setiabudi; Resti Yudhawati
Jurnal Respirasi Vol. 8 No. 1 (2022): January 2022
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (300.067 KB) | DOI: 10.20473/jr.v8-I.1.2022.1-6

Abstract

Introduction: An important concern regarding TB currently is the case of anti-TB drug resistance; hence research on resistance patterns and risk factors is essential. This study aimed to identify the pattern of first-line anti-TB drug resistance. Methods: This descriptive retrospective study was conducted at MDR-TB polyclinic Dr. Soetomo General Hospital, Surabaya, in 2017-2019. Only complete medical records were included. The variables were first-line anti-TB drug resistance (isoniazid, rifampicin, ethambutol, streptomycin) and patients’ characteristics (age, gender, treatment history, and comorbidities). The drug resistance test was performed using certified culture methods. Results: Among 239 patients, the incidences of resistance to H, R, E, and S were 79.08%, 94.14%, 25.94%, and 20.08%, respectively. The most common patterns were HR (42.26%), R (18.83%), and HRE (12.55%). The largest age group was 45-54 years old (38%). The dominant gender was male (56.49%). The most treatment history category was relapsed patients (48%) and there were more patients with comorbidity (57%). Conclusion: The highest incidence rate of resistance was rifampicin and the most common resistance pattern was HR. Most of the patients were of working age, male, relapse patients, and had comorbidities. An appropriate TB therapy treatment plays an important role in preventing resistance.
Co-Authors Rebekah Setiabudi, Rebekah Resti Yudhawati